Inovio Pharmaceuticals Inc

NASDAQ:INO   3:59:56 PM EDT
4.28
-0.48 (-10.00%)
4:47:31 PM EDT: $4.28 +0.01 (+0.12%)
Products, Regulatory

Inovio Highlights Key Updates On Phase 3 Program For VGX-3100

Published: 12/14/2021 13:21 GMT
Inovio Pharmaceuticals Inc (INO) - Inovio Highlights Key Updates on Phase 3 Program for Vgx-3100, Its Dna-based Immunotherapy for the Treatment of Cervical Hsil Caused by Hpv-16 And/or Hpv-18.
Inovio Pharmaceuticals Inc - Completes Enrollment of Reveal2.
Inovio Pharmaceuticals Inc -.
Inovio Pharmaceuticals Inc - Long-term Data Favorable From Reveal1.
Inovio Pharmaceuticals Inc - First Participant Has Been Dosed in Phase 3 Trial of Vgx-3100 for Cervical Hsil in China.
Inovio Pharmaceuticals Inc - Advancing Its Partnership With Qiagen to Co-develop a Liquid Biopsy-based Diagnostic Product.
Inovio Pharmaceuticals Inc - Anticipates Having Additional Information on Its Biomarker Development in 2022.